法国初创公司Ziwig开发的唾液检测工具Ziwig Endotest正在英国和法国用于诊断子宫内膜异位症，声称能够准确识别97%的患者和93%的非患者1。该检测费用约为2000美元1。法国一项涉及2500名女性的研究预计在今年晚些时候公布结果1，英国试验已启动并计划运行三年1。
澳大利亚医学专家对这一检测工具在本国的应用前景表示谨慎态度，认为在引入前需要获得更多真实世界数据的支持1。澳大利亚每7名18-45岁女性中约有1人患子宫内膜异位症1，患者平均需等待6-8年才能获得诊断1。澳大利亚妇产科学院（RANZCOG）去年更新了诊疗指南，建议采用经阴道超声而非腹腔镜手术作为首选诊断方法1。
专家表示虽然希望有更好、更安全、更便宜、更易获得的检测方法，但该工具作为"一个概率测试，不是真正设计作为诊断测试的"存在局限性1。医学界也强调应当尽早对患者症状进行治疗，而不必等待正式确诊1。
A saliva-based diagnostic tool for endometriosis developed by French startup Ziwig is currently undergoing trials in the United Kingdom and France, with the company claiming it can accurately identify 97% of patients with the condition and 93% of those without it 1. The test, called Ziwig Endotest, costs approximately $2,000 USD 1. A study involving 2,500 women in France is expected to release results later this year, while a UK trial has already begun with an anticipated three-year timeline 1.
Despite these developments, Australian medical experts are expressing caution about adopting the technology without additional real-world evidence 1. Dr Polyakov characterized the test as "a probability test, not one truly designed as a diagnostic test" 1, highlighting concerns about its clinical application. Dr Druitt acknowledged the need for improved screening methods, stating: "We want better detection methods, ones that are safer, cheaper and more accessible" 1. Australian guidelines updated by RANZCOG last year now recommend transvaginal ultrasound rather than laparoscopic surgery as the preferred diagnostic approach 1.
The diagnostic burden facing Australian women with endometriosis underscores the relevance of this scrutiny. Approximately one in seven women aged 18–45 in Australia have the condition 1, yet they wait an average of 6–8 years to receive a diagnosis 1. Experts emphasize the importance of addressing symptoms early rather than delaying treatment pending confirmation 1.
评论
还没有评论，欢迎留下第一条。